Pharmacodynamic & Predictive Biomarkers in Clinical Development of JTX-2011 - Beth Trehu, MD - Jounce Therapeutics
Immune Checkpoint Modulator Clinical Combinations E-Book
Past Presentation: Development of Small Molecule Checkpoint Inhibitors (David Tuck, CMO Curis Inc)
Past Presentation: Cancer Cell-Intrinsic Features of Response to Immune Therapies in Melanoma (Scott E. Woodman, MD Anderson Cancer Center)
Past Presentation: What Are The Key Issues In The Design Of Combination Checkpoint Inhibitor Trials? (Michael Postow, Memorial Sloan Kettering Cancer Center)
Past Presentation: Targeting CD47 to Involve Macrophages & Dendritic Cells in a Holistic Anti-Tumor Immune Response (Marie Kosco-Vilbois, NovimmuneSA)
Immune Checkpoint Inhibitors 2015: What Our Partners Say About Us
Thought leaders across pharma, biotech and academia gathered at Immune Checkpoint Inhibitors to crack the road blocks preventing further progress in the immuno-oncology field.